



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

| APPLICATION NO.   | FILING DATE | FIRST NAMED INVENTOR          | ATTORNEY DOCKET NO.        | CONFIRMATION NO. |
|---|-------------|-------------------------------|----------------------------|------------------|
| 09/334,325  | 06/16/1999  | STEWART A. CEDERHOLM-WILLIAMS | CV0276A                    | 5209             |
| 7590  | 06/16/2006  |                               |                            |                  |
| T R FURMAN<br>BRISTOL-MYERS SQUIBB COMPANY<br>100 HEADQUARTERS PARK DRIVE<br>SKILLMAN, NJ 08558 |             |                               | EXAMINER<br>CHEN, SHIN LIN |                  |
|   |             |                               | ART UNIT                   | PAPER NUMBER     |
|   |             |                               | 1632                       |                  |

DATE MAILED: 06/16/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

**Advisory Action  
Before the Filing of an Appeal Brief**

Application No.

09/334,325

Applicant(s)

CEDERHOLM-WILLIAMS,  
STEWART A.

Examiner

Shin-Lin Chen

Art Unit

1632

**--The MAILING DATE of this communication appears on the cover sheet with the correspondence address --**

THE REPLY FILED 27 April 2006 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE.

1. ☐ The reply was filed after a final rejection, but prior to or on the same day as filing a Notice of Appeal. To avoid abandonment of this application, applicant must timely file one of the following replies: (1) an amendment, affidavit, or other evidence, which places the application in condition for allowance; (2) a Notice of Appeal (with appeal fee) in compliance with 37 CFR 41.31; or (3) a Request for Continued Examination (RCE) in compliance with 37 CFR 1.114. The reply must be filed within one of the following time periods:

- a) ☐ The period for reply expires \_\_\_\_\_ months from the mailing date of the final rejection.  
b) ☐ The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection.

Examiner Note: If box 1 is checked, check either box (a) or (b). ONLY CHECK BOX (b) WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).

Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**NOTICE OF APPEAL**

2. ☒ The Notice of Appeal was filed on 22 May 2006. A brief in compliance with 37 CFR 41.37 must be filed within two months of the date of filing the Notice of Appeal (37 CFR 41.37(a)), or any extension thereof (37 CFR 41.37(e)), to avoid dismissal of the appeal. Since a Notice of Appeal has been filed, any reply must be filed within the time period set forth in 37 CFR 41.37(a).

**AMENDMENTS**

3. ☐ The proposed amendment(s) filed after a final rejection, but prior to the date of filing a brief, will not be entered because  
(a) ☐ They raise new issues that would require further consideration and/or search (see NOTE below);  
(b) ☐ They raise the issue of new matter (see NOTE below);  
(c) ☐ They are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or  
(d) ☐ They present additional claims without canceling a corresponding number of finally rejected claims.

NOTE: \_\_\_\_\_. (See 37 CFR 1.116 and 41.33(a)).

4. ☐ The amendments are not in compliance with 37 CFR 1.121. See attached Notice of Non-Compliant Amendment (PTOL-324).  
5. ☒ Applicant's reply has overcome the following rejection(s): 35 U.S.C. 112 second paragraph.  
6. ☐ Newly proposed or amended claim(s) \_\_\_\_\_ would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).  
7. ☒ For purposes of appeal, the proposed amendment(s): a) ☐ will not be entered, or b) ☒ will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended.  
The status of the claim(s) is (or will be) as follows:  
Claim(s) allowed: None.  
Claim(s) objected to: None.  
Claim(s) rejected: 1 and 13-16.  
Claim(s) withdrawn from consideration: None.

**AFFIDAVIT OR OTHER EVIDENCE**

8. ☐ The affidavit or other evidence filed after a final action, but before or on the date of filing a Notice of Appeal will not be entered because applicant failed to provide a showing of good and sufficient reasons why the affidavit or other evidence is necessary and was not earlier presented. See 37 CFR 1.116(e).  
9. ☐ The affidavit or other evidence filed after the date of filing a Notice of Appeal, but prior to the date of filing a brief, will not be entered because the affidavit or other evidence failed to overcome all rejections under appeal and/or appellant fails to provide a showing a good and sufficient reasons why it is necessary and was not earlier presented. See 37 CFR 41.33(d)(1).  
10. ☐ The affidavit or other evidence is entered. An explanation of the status of the claims after entry is below or attached.

**REQUEST FOR RECONSIDERATION/OTHER**

11. ☒ The request for reconsideration has been considered but does NOT place the application in condition for allowance because:  
See Continuation Sheet.  
12. ☐ Note the attached Information Disclosure Statement(s). (PTO/SB/08 or PTO-1449) Paper No(s). \_\_\_\_\_.  
13. ☐ Other: \_\_\_\_\_.

**SHIN-LIN CHEN  
PRIMARY EXAMINER**

Shin-Lin Chen  
Primary Examiner  
Art Unit: 1632

Continuation of 11. does NOT place the application in condition for allowance because: Applicant argues that the 35 U.S.C. 112 first rejection is simply a rejection under 35 U.S.C. 101 in the guise of a rejection under 35 U.S.C. 112. Applicant further argues that the law does not require elucidation of the mechanism of cell transformation, does not require to increase or enhance cell transformation efficiency, or every possible way to administer his invention, and the claims require applying a nucleic acid to a cell and adhering a gel to the cell so as to entrap the nucleic acid (amendment, p. 3-4). Applicant's arguments are exactly the same as the arguments in the amendment filed 11-30-05. Therefore, those arguments are not found persuasive because of the reasons of record. The claims are directed to a method of transforming a cell in vitro and in vivo via various administration routes, and encompass applying a nucleic acid to a cell first and then applying a pliable, adhesive fibrin gel to said cell so as to transform the cell in vivo at any location of any subject including human beings, mammals, fishes, birds, insects, fungus, plants etc., via various administration routes. The specification must provide sufficient enabling disclosure to support the enablement of the claimed invention but fails to do so. The specification fails to provide adequate guidance and evidence for transforming a cell in vitro or in vivo by applying a nucleic acid, such as a vector or a virus carrying the nucleic acid, to the cell first and then applying a pliable, adhesive fibrin gel to said cell so as to transform the cell in vitro or in vivo at any location of any subject via various administration routes.